The Role of Gilteritinib in the Treatment of Relapsed or Refractory FLT3-Mutated AML¹
Video
Video of case report 2:
In this interview Dr. A. de Voeght (Sart Tilman-CHU Liège; Belgium), discusses his experiences with gilteritinib as a bridging therapy from auto-HSCT2 to allo-HSCT2
Intended for: practitioners hematology Why: up-to-date knowledge TKI3 related target therapy When: Watch now Duration: 4 minutes